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1. Introduction 
Hemophilia A and B are hereditary bleeding disorders caused by a deficiency of coagulation 
factors VIII (FVIII) and IX (FIX), respectively. In substitution therapies using FVIII and FIX 
concentrates for the management of bleeding, the development of inhibitory antibodies is a 
serious complication in ~28% and ~7% of hemophilia A and B patients, respectively [1, 2].  
Currently, two bypassing agents, plasma-derived activated prothrombin complex 
concentrates (APCC, FEIBA®) and recombinant activated factor VII (rFVIIa, NovoSeven®), 
are available for the management of bleeding in hemophilia patients with inhibitors 
including acquired hemophilia patients. Retrospective studies showed the efficacy of rFVIIa 
and APCC in 12~36 h in a standard administration regime is assessed to be 66~95% and 
39~76%, respectively [3]. A recent comparative study seemed to indicate equivalence 
between rFVIIa and APCC [4]; however, a considerable number of patients experience 
treatment failure or insufficient efficacy.  
In 2002, an anecdotal report suggested that the sequential administration of rFVIIa and 
prothrombin complex concentrate (PCC) to hemophilia patients with inhibitors in order to 
obtain a stronger hemostatic effect than with rFVIIa alone [5]. Further, it has been reported 
that the combination of rFVIIa and APCC appeared to confer beneficial hemostatic synergy 
in patients refractory to each individual therapy [6-8]. However, repeated infusion of APCC 
may cause an accumulation of prothrombin and factor X (FX), thereby increasing the risk of 
thrombosis. Moreover, a lack of suitable laboratory tests for monitoring hemostatic effects is 
a major concern with current bypassing therapies. As a consequence and in appreciation of 
the incomplete efficacy and safety of currently available bypassing agents, new drugs are in 
development, such as rFVIIa analogues featuring higher hemostatic potential [9], 
glycoPEGylated rFVIIa with a longer half-life than rFVIIa [10], and non-anticoagulant 
sulphated polysaccharides (AV513) [11].  
In order to solve these problems, we searched for alternative factors for enhancing and 
promoting FVIIa’s hemostatic activity, and found that a combination of plasma-derived 
FVIIa and FX (FVIIa/FX) may overcome the disadvantages of rFVIIa therapy for hemophilia 
patients with inhibitors. That combination allows improving APTT remarkably in the 
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patient plasma which is useful laboratory test for monitoring the hemostatic effect of 
hemophilia patients. An FVIIa/FX mixture, MC710, was designed as a dry-heated product 
prepared by mixing plasma-derived FVIIa and FX at a weight ratio of 1:10 under acidic 
conditions to suppress the generation of FXa.  
A Phase I clinical study encompassing pharmacokinetics (PK), pharmacodynamics (PD), 
and safety has been completed. In this article, we outline the rationale for the combined use 
of FVIIa and FX, the manufacturing method of MC710, the treatment’s prospective efficacy 
and safety, and in the final section, the results of Phase I clinical study in non-bleeding 
hemophilia patients with inhibitors. 
2. Rationale for the combination of FVIIa and FX  
2.1 Background  
The blood coagulation system involves a so-called “cascade reaction” of enzymes and 
substrates which finally achieves the formation of a fibrin clot. In this reaction, Ca2+ and 
phosolipids (PL) assume the role of cofactors which remarkably enhance the affinity 
between enzymes and substrates, resulting in the promotion of a coagulation reaction at the 
site of injury.  
FVIIa circulates in blood at a concentration of around 0.1 nM (3~5 ng mL-1) in plasma [12, 
13] with a much longer half life, 2~3 h, than other activated coagulation factors because of its 
zymogen-like conformation [14]. Tissue factor (TF) is a membrane glycoprotein expressed in 
various tissues and plays the role of a cofactor of FVIIa. Vascular TF is present in the 
adventitia, hidden from the circulating blood. When a vessel is injured, TF is exposed at the 
site. FVIIa binds to TF forming a stoichiometric complex (the initiator of the extrinsic 
pathway) and remarkably enhances catalytic activity to activate FIX and FX. FIXa forms a 
FIXa/FVIIIa/PL complex (FXase) and converts FX to FXa. Also, FXa forms a FXa/FVa/PL 
complex (prothrombinase) and converts prothrombin to thrombin. Thrombin activates FXI 
to form FXIa and promotes the activation of FIX (feedback activation of the intrinsic 
pathway), and converts the fibrinogen to a fibrin clot via limited proteolysis [15]. Platelets 
are essential for hemostasis. In the artery, circulating platelets in blood attach and adhere to 
the extracellular matrix (collagen) under the layer of endothelial cells at the site of damage 
using GPVI and integrin 21 (GPIa/IIa), and adhere to the collagen via the interaction of 
VWF (von Willebrand factor) and GPIbIX, and finally aggregate through the interaction of 
IIb3(GPIIb/IIIa)and VWF/fibrinogen [16-19]. Through these processes, localized platelets 
are activated by thrombin or chemical mediators (ADP, et al) released from activated platelet 
granules. The PL membrane essential for thrombin generation is mainly supplied by the 
activated platelets.  
In the hemostasis of hemophilia patients with inhibitors against FIX or FVIII, the intrinsic 
pathway is completely blocked. Therefore, it is necessary to enhance the potential for 
coagulation based on the extrinsic pathway, the activation of FX by FVIIa, followed by the 
activation of prothrombin to form thrombin. 
In 1996, rFVIIa therapy was launched to give a super-physiological concentration to the 
patient plasma to enhance the extrinsic pathway of hemophilia patients with inhibitors. 
However, the mechanism of the bypassing activity of rFVIIa is controversial due to the 
requirement for a high dose (60~120 µg kg-1), which gives a high FVIIa concentration in 
plasma (0.5~1.0 µg mL-1) [20]. 
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There are two hypotheses to elucidate the requirement for the high dose (Fig. 1-A). The first 
is “TF-dependent FX activation”. It was reported that rFVIIa-induced thrombin generation 
in the presence of a low concentration of TF and in the absence of FVIII is inhibited by 
physiological concentrations of FVII, and at least 10 nM (0.5 µg mL-1) of rFVIIa is required to 
overcome the inhibition by FVII in order to induce the bypassing activity [21, 22]. The 
second is “TF-independent FX activation”. It was reported that 5 nM (0.25 µg mL-1) of rFVIIa 
could convert FX to FXa on the surface of activated platelets, leading to thrombin generation 
independent of TF [23]. Clinical experience has suggested that the dose or blood level of 
rFVIIa required for hemostasis in any given hemophilia patient with inhibitors is not always 
predictable. Differences in platelet procoagulant properties could influence the response to a 
high-dose of rFVIIa [24, 25]. Also, it has been reported that rFVIIa binds to GPIbIX on 
activated platelets and localizes at the site of injury [26]. Recently, mega-dose therapy with 
an injection of rFVIIa (270 µg kg-1) has been applied to the control of bleeding to diminish 
repeated administrations in 2~3 h and raise the hemostatic potential of rFVIIa by increasing 
the Cmax in plasma above the standard dose [27, 28].  
The exact mechanism of rFVIIa is not clear at present, but its potential for FXa and thrombin 
generation and subsequent fibrin clot formation will be essential to obtain a hemostatic 
effect with rFVIIa, in either a TF-dependent or TF-independent manner.  
2.2 Rationale for the combined use of FVIIa and FX 
It was reported that TF binds to FX or FIX as well as to FVIIa and this ternary complex of 
enzyme/cofactor/substrate (FVIIa/TF/ FIX or FX) is the real trigger of the extrinsic 
pathway to generating FIXa or FXa and the subsequent generation of thrombin [29-31]. 
However, it was demonstrated that FIX is a much better substrate for FVIIa-TF than FX [32]. 
We investigated the kinetic parameters of FVIIa-mediated FX activation under several 
conditions. The results of the kinetic analysis are shown in Table 1. Km values in the 
presence of PL and relipidated TF were 180 ± 70 nM and 160 ± 60 nM, while kcat values were 
0.38 ± 0.09 s-1 and 11.5 ± 4.7 s-1, respectively, similar to values published previously [32]. The 
FX level in normal plasma is 8~12 μg mL-1 (140~210 nM) [34], and the Km values were within 
this range; therefore, it was suggested that the FX concentration in plasma might not be 
sufficient to achieve the generation of FXa by FVIIa required for hemostasis (Fig. 1-B). These 
results indicate that a higher concentration of FX is required to enhance the catalytic efficacy 
of FVIIa and to complete coagulation in the plasma of hemophilia patients.  
 
     
Assay conditions Concentration Km kcat kcat/Km 
  µM s-1 s-1 μM-1 
Ca2+ 5 mM 72.4 0.000135 0.00000187 
Ca2+/PCPSa) 5 mM/10 µM 0.18±0.07 0.38±0.09 2.20±0.34 
Ca2+/PCPS/TF 5 mM/10 µM/100 pM 0.16±0.06 11.5±4.7 73.1±14.3 
Ca2+/activated platelets b) 5 mM/1.5×105 cells µL-1 1.72±0.4 0.77±0.21 0.48±0.19 
The activation of FX was carried out in the presence or absence of PL (10 µM) and relipidated TF (100 
pM TF/10 µM PL) in a solution containing 5 mM CaCl2 [33].  
a) Reconstituted phosphatidylcholine and phosphatidylserine vesicles (PCPS; weight ratio 7:3) were 
used as phospholipids.  
b) Platelets were activated by the thrombin receptor activation peptide (TRAP). 
Table 1. Steady-state kinetics of FX’s activation by FVIIa 
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FVIIa
TF/phospholipid
or 
Activated platelets
(A) FVIIa induced FXa generation
FX FXa
Vmax
Vmax/2
(B) Kinetic analysis of FVIIa to FX
2~3 x KmKm
FVIIa: 20~40 nM in plasma
(standard rFVIIa therapy)
FX: 200~400 nM in plasma
(≒ 2~3 x Km FX)
Km ≒ FX conc. in plasma (140~210 nM)
 
(A) FVIIa induced FXa generation. The activation of FX is essential for FVIIa to generate bypassing 
activity. For the elucidation of the requirement for high rFVIIa concentrations (>1 μg mL-1 in plasma) in 
rFVIIa therapy, there are two hypotheisies: “TF-dependent FX activation” [21, 22] and “TF-independent 
FX activation” [23-26] (refer to the text for details). (B) Kinetic analysis of FVIIa to FX. In the activation 
of FX by FVIIa, the activation rate (y-axis) increases depending on the substrate (FX) concentration (x-
axis). As shown in Table 1, Km values in the presence of PL and relipidated TF were in the range of FX 
levels in normal plasma (140~210 nM), and the Km value in activated platelets is far above that range. In 
the extrinsic pathway, the increase of FX concentration in plasma two or three times (2~3 x Km) might 
facilitate the increase of the FX actvation rate, and promote the formation of FVIIa/TF/FX complex. 
Fig. 1. Advantage of co-administration of FVIIa and FX 
The results of the kinetic analysis were consistent with those of the thrombin generation 
(TG) assay (Fig. 2). TG assay using a fluorosubstrate (Z-G-G-R-MCA) specific for thrombin 
was developed by Hemker et al [35]. In this assay system, thrombin generation is analyzed 
in the following three steps [36, 37]:  
1. Initiation: initiation of the cascade reaction to start thrombin generation.  
2. Propagation: explosive thrombin production. 
3. Termination: attenuation of thrombin generation.  
The TG assay is used to analyze the clinical efficacy of rFVIIa and APCC [38]. The TG 
parameters are lag time (time to initial thrombin formation (min)), peak thrombin level 
(nM), time to peak (ttPeak) (min), and endogenous thrombin potential (ETP) (nM min) [39]. 
We used this assay to examine the hemostatic potential of the combination of FVIIa and FX. 
The thrombin-generating potential of hemophilic plasma was raised by increasing the 
concentration of FX added to the plasma in the range of 2.5~20 μg mL-1 without the addition 
of FVIIa (Figs. 2A-a and 2B-a). Further, the combination of FVIIa (0.25 and 1.0 μg mL-1) and 
FX (2.5~20 μg mL-1) gave more thrombin-generating potential to the plasma than did FVIIa 
alone, resulting in a shortening of the ttPeak and an increase in the peak thrombin level 
(Figs. 2A-b and -c, and 2B-b and -c) [40]. 
It has been estimated that the half-life of FVIIa is around 3 h and that of FX is 24~56 h [41-
43]. Following the simultaneous administration of FVIIa and FX, the amount of FVIIa should 
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decrease faster than that of FX, but a high FX level might help to generate bypassing activity 
which results in longer-lasting hemostatic potential than FVIIa alone. This idea was proven 
in our previous experiment using a monkey acquired hemophilia B model in which the 
hemostatic efficacy of FVIIa/FX (co-administration of FVIIa (80 μg kg-1) and FX (800 μg kg-1)) 
and FVIIa aloneȐ80 μg kg-1ȑwas compared by measuring thromboelastography (TEG). As 
shown in Fig. 3, administration of FVIIa/FX remarkably normalized TEG parameters. Even 
6 h after its administration, FVIIa/FX had hemostatic potential above that immediately after 
the administration of FVIIa alone [44]. 
 
 
TG in plasma of a hemophilia A patient with inhibitors (FVIII INP; 101 BU mL-1) or FIX-depleted 
plasma (FIX-DP) at various concentrations of FVIIa and FX with relipidated TF. Panels a~c of A (FVIII 
INP) and B (FIX-DP): FVIIa 0, 0.25, and 1.0 µg mL-1. Added FX concentration in the plasma from top to 
bottom in each panel: 0 µg mL-1, - ; 2.5 µg mL-1, - ; 5.0 µg mL-1, - ;10 µg mL-1, - ;20 µg mL-1, - . 16.7 
pM TF and 0.83 μM PL were used for the assay. 
Fig. 2. Changes in TG profiles induced by FX on FVIIa in hemophilic plasma(40) 
APTT is used for monitoring the management of bleeding or determining the supplemental 
level of FVIII or FIX concentrate in hemophilia patients, but not in therapy using bypassing 
agents because of the poor improvement. We reported that more than 5 µg mL-1 of FVIIa 
alone is required to reduce APTT in hemophilic plasma to levels equivalent to those after 
replacement-therapy (10 % of FVIII or FIX activity in hemophilic plasma); on the other hand, 
the mixture of FX and FVIIa caused a significant improvement of APTT in a concentration-
dependent manner. In plasma containing 0.5~1.5 μg mL-1 of FVIIa (obtained after 
intravenous rFVIIa administration at standard doses) when FX is added at 5~15 μg mL-1, the 
poor coagulant activity in hemophilic plasma is remarkably improved to levels achieved 
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with replacement therapy [44]. Therefore, a mixture ratio 1: 10 of FVIIa to FX in MC710 was 
designed to optimize the bypassing effect of FVIIa (0.5~1.5 μg mL-1 ) in plasma.  
 
 
A hemophilia B model using a cynomolgus monkey was produced by the administration of goat anti-
FIX antibodies to be in < 5% of FIX activity. FVIIa (80 µg/kg) was administered to the monkey and 
Thromboelastography (TEG) was measured pre-administration, and 6 h and 12 h post-administration. 
Also, FVIIa (80 µg/kg) and FX (800 µg/kg) were continuously injected into the monkey. The TEG 
patterns are shown in the figure and r + k values are described on the right side of each pattern. ND 
means “not detected”. 
Fig. 3. Changes in TEG patterns in the monkey acquired hemophilia B model pre/post 
injection of FVIIa or FVIIa/FX(44) 
3. Outline of the manufacture of the FVIIa/FX mixture (MC710) 
MC710 is a lyophilized mixture of FVIIa and FX prepared from pooled human plasma. FVII 
and FX are vitamin K-dependent proteins containing a strongly negatively charged amino 
acid, -carboxy-glutamic acid. The purification of those proteins takes into account specific 
properties such as high acidity and Ca2+-dependent conformational change. The conversion 
of FVII to FVIIa is a key process in the production of the FVIIa preparation. In 1986, Bjoern et 
al. reported that rFVII is autocatalytically activated to rFVIIa on an anion exchange column 
[45]. On an industrial scale, the activation of FVII on an anion exchange resin is very useful 
because it does not require any other proteases to activate FVII such as FXa, FIXa, and FXIIa. 
In the production of plasma-derived FVIIa, FVII is converted to FVIIa with the following 
two steps to achieve high recovery and quality: (1) partial activation on anion exchange 
resin and, (2) further activation in the solution after eluting from the resin [46]. A flow 
diagram of the preparation of MC710 is shown in Fig. 4. In the first purification step, a crude 
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vitamin K-dependent protein fraction is extracted from cryoprecipitate-poor plasma using 
anion exchange chromatography. Next, this fraction is applied to an immunoaffinity 
chromatography column containing gels bound with Ca2+-dependent anti-FVII or anti-FX 
monoclonal antibody as a ligand. The FVII or FX fraction eluted with a buffer containing 
EDTA is treated in solvent and detergent (0.3% TNBP and 1% polysorbate 80) for virus 
inactivation. After the treatment, the FVII fraction is applied to DEAE Sepharose-FF to 
obtain partially activated FVIIa and the eluted FVII/FVIIa mixture is completely converted 
to FVIIa in the solution. The FX fraction eluted from the immunoaffinity chromatography  
 
 
Preparation of FVIIa/FX mixture (1 : 10)
Dry-heat treatment at 65℃ for 96 h
Cryopreciptate poor plasma
Anion exchange chromatography
Filling and lyophylization
Affinity chromatography I
(Anti-FVII MoAb-immobilized gel)
Affinity chromatography II
(Anti-FX MoAb-immobilized gel)
S/D treatment
Nanofiltration (15nm)
FVIIa
FX
Nanofiltration (15nm)
S/D treatment
Anion exchange chromatography Anion exchange chromatography
Hydrophobic chromatography
 
 
 
FVII and FX are purified using immunoaffinity gel coupled with anti- FVII and -FX antibodies, 
respectively. Purified fractions are treated with solvent and detergent (0.3% TNBP and 1% polysorbate 
80) for inactivation of the enveloped virus, and purified samples are filtered with a nano-filter of 15-nm 
pore size (Planova® 15N) for virus elimination. The specific activity of the prepared FVIIa and FX was 
48.1 ± 0.5 IU/µg (n=5) and 159.1 ± 4.4 IU/mg (n=6), respectively. After mixing FVIIa and FX with the 
stabilizers, the solution is dispensed to the vials and lyophilized, then heated at 65°C for 96 h. 
Fig. 4. Outline of manufacturing methods of MC710 
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column is further purified using anion exchange and hydrophobic interaction 
chromatographies. These purified samples are filtered with a nano-filter (Planova® 15N) 
of 15-nm pore size for virus elimination. The concentrated FVIIa and FX are mixed at a 
weight ratio of 1:10 under acidic conditions of pH5.5~5.9 for suppression of FXa 
generation, and then lyophilized. Finally, the lyophilized FVIIa and FX mixture  
is dry-heated at 65°C for 96 h for virus elimination. MC710 is formulated with FVIIa  
(0.6 mg mL-1), FX (6 mg mL-1), antithrombin (1.0 U mL-1), and human serum albumin 
(2.0%) after reconstitution [40]. 
4. Prospective efficacy and safety of MC710 
4.1 APTT and PT waveform analysis  
APTT waveforms are used to analyze the overall process of fibrin clotting by measuring the 
turbidity and calculating the coagulation rate (dT/dt) and coagulation acceleration (second 
derivative of transmittance and time; d2T/dt2). It was reported that these parameters are 
useful for the diagnosis of DIC [47, 48]. Recently, Shima reported that APTT waveforms are 
applicable to the quantification of low levels of FVIII (<1 U dL-1) on the basis of the 
correlation of the FVIII activity with coagulation acceleration, and the waveform profile 
formed by rFVIIa was different from that for normal plasma [49]. In our analysis, MC710 
with a FVIIa concentration of 1 µg mL-1 (the dose and concentration in plasma of MC710 are 
expressed as FVIIa amounts) exhibited greater clotting ability than 1 µg mL-1 FVIIa alone in 
hemophilia A patient plasma with inhibitors and FIX-deficient plasma samples (Figs. 5A-a 
and 5B-a). Coagulation acceleration showed that MC710 at above 1-2 g mL-1 possessed a 
greater ability to shorten APTT and to induce accelerated clotting than did the same 
concentration of rFVIIa (Figs. 5A-b and 5B-b). Parameters for plasma from hemophilia A 
patients with inhibitors in the presence of 1 U mL-1 APCC were similar to those in the 
presence of 1 µg mL-1 MC710 (Figs. 5A-a and 5A-b). On the other hand, PT and its clot 
formation acceleration did not show any difference among the three agents (data not 
shown).  
4.2 TG assay  
The thrombin generation of hemophilia A patient plasma with inhibitors and FIX-depleted 
plasma was measured at various concentrations of rFVIIa, MC710, and APCC. MC710 
(0.1~8.0 μg mL-1) and APCC (0.25~2.0 U mL-1) exhibited conspicuous concentration-
dependent changes in thrombin generation profiles (Figs. 6A-b, 6B-b, and 7B-a). 
Reportedly, a mega-dose (270 μg kg-1 b.w.) of rFVIIa can achieve rFVIIa concentrations of 
3~5 μg mL-1 in hemophilic plasma [27, 28]; however, the thrombin-generating potential of 
rFVIIa in plasma did not change at over 1 μg mL-1 of rFVIIa (Figs. 6A-a and 6B-a). 
To evaluate the TF-specificity of the agents, thrombin generation in plasma of a hemophilia 
patient with inhibitors was measured in the presence or absence of relipidated TF or PL at 
various concentrations of MC710 and APCC, and 1.0 μg mL-1 of rFVIIa (Figs. 7A-a~c  
and 7Ba~c). The 0.1 μg mL-1 of MC710 and 0.25 U mL-1 of APCC showed a greater thrombin 
generation potential than 1.0 μg mL-1 of rFVIIa (Figs. 7A-a and 7B-a). MC710 showed lower 
thrombin-generating potential than did APCC in the absence of TF or PL (Figs. 7A-b and -c, 
and 7B-b and -c). These results suggest that MC710 has a relatively high specificity for TF 
compared to APCC. 
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APTT waveforms of plasma from a hemophilia A patient with inhibitors (FVIII INP; 140 BU mL-1) and 
FIX-depleted plasma (FIX-DP) at various concentrations of the bypassing agents. Panels A-a and A-b: 
APTT and coagulation acceleration of FVIII INP containing rFVIIa (NovoSeven®) (0.1~8.0 µg mL-1, □), 
MC710 (0.1~8.0 µg mL-1, ■), and APCC (FEIBA®) (0.25~4.0 U mL-1). Panels B-a and B-b: APTT and 
coagulation acceleration of FIX-DP containing rFVIIa (0.1~8.0 µg mL-1, □), MC710 (0.1~8.0 µg mL-1, ■). 
Normal plasma (”Normal”) or FIX-DP supplemented with FIX at 1 U mL-1 was used as a control. The 
MC710 concentration is denoted by the FVIIa concentration in each panel. 
Fig. 5. Changes in APTT waveforms induced by rFVIIa, APCC, and MC710(40) 
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TG in plasma of a hemophilia A patient on inhibitors (FVIII INP; 70 BU mL-1) and FIX-depleted plasma 
(FIX-DP) at various concentrations of the bypassing agents with relipidated TF. Panels A-a and -b: TG 
of FVIII INP; rFVIIa (NovoSeven®) (A-a, 0.1~8 µg mL-1) and MC710 (A-b, 0.1~8.0 µg mL-1). Panels  
B-a and -b: TG of FIX-DP, rFVIIa (B-a, 0.1~8.0 µg mL-1), MC710 (B-b, 0.1~8.0 µg mL-1). The gray lines 
signify the results in normal plasma (”Normal”) for A-a and -b and FIX-DP supplemented with  
FIX 1.0 U mL-1 for B-a and B-b used as control plasma. The MC710 concentration is denoted by the FVIIa 
concentration in each panel. In the TG assay, 16.7 pM TF and 0.83 μM PL were used. Each TG profile 
represents the results of three experiments. 
Fig. 6. Changes in TG profiles induced by rFVIIa and MC710(40) 
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TG in plasma of a hemophilia A patient on inhibitors (38 BU mL-1) with relipidated TF or phospholipids 
or without relipidated TF at various concentrations of the bypassing agents. Panels A- and B-a~c: a) 
addition of relipidated TF, b) addition of phospholipids, c) no addition of relipidated TF at the 
concentrations of MC710 (0.1~2.0 µg mL-1; panels A a~c) and APCC (FEIBA®) (0.25-2.0 U mL-1;  
panels B a~c). TG in the presence of rFVIIa (NovoSeven®) (1.0 µg mL-1) is inserted in each panel. The 
MC710 concentration is denoted by the FVIIa concentration in each panel. Each TG profile represents 
the results of three experiments. In the TG assay, 16.7 pM TF and 0.83 μM PL were used. 
Fig. 7. Changes in TG profiles induced by APCC and MC710 with or without TF(40) 
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4.3 Thrombogenic test using monkeys 
It was reported that APCCs might induce thrombotic complications such as disseminated 
intravascular coagulation (DIC) and acute myocardial infarction [50-52]. As the clearance of FX 
is much slower than that of FVIIa, repeated administrations of MC710 might induce the 
accumulation of FX in the blood raising concerns over safety regarding DIC or other 
thrombotic events. Therefore, it is important to confirm the safety of repeated administrations 
of MC710 alone and in combination with other bypassing agents. We performed multiple 
injections of MC710 (4 injections of 120 g kg-1 every 8 h (as FVIIa dose)), and rFVIIa (one 
injection of 90 g kg-1 and 2 injections of 120 g kg-1 every 2 h) or APCC (3 infusions of 100 U 
kg-1 every 12 h) at 8 h after the administration of MC710 (120 g kg-1) into the monkeys, and 
compared the DIC parameter changes with those of APCC (4 infusion of 100 U kg-1 every 12 h) 
(Fig. 8). No serious or severe event was observed in any monkey or in any group, and the 
fibrinogen level and platelet counts did not change. However, the FDP (fibrinogen degraded 
products) level increased in all groups and the rate of increase was lower in the group 
repeatedly administered MC710 than that repeatedly administered APCC (See the legend in 
Fig. 8). These results suggest the thrombogenic risk from the repeated administration of 
MC710 is equal to or lower than that of repeated administration of APCC. 
 
a) MC710 
b) MC710 →APCC
c) MC710 →rFVIIa
d) APCC
MC710
120 g kg-1 
MC710
120 g kg-1 
MC710
120 g kg-1 
MC710
120 g kg-1 
APCC
100 U kg-1 
APCC
100 U kg-1 
APCC
100 U kg-1 
rFVIIa
120 g kg-1 
rFVIIa
120 g kg-1 
APCC
100 U kg-1 
APCC
100 U kg-1 
APCC
100 U kg-1 
8 h 8 h 8 h
8 h
8 h
12 h
2 h 2 h
12 h
12 h 12 h 12 h
APCC
100 U kg-1 
rFVIIa
90 g kg-1 
 
Thrombogenicity of MC710 was compared to APCC (FEIBA®) using cynomolgus monkeys. The 
experimental design is described in the figure. Schemes a)~c) show the time courses of injections or 
infusions of rFVIIa (NovoSeven®) and APCC after 120 µg kg-1of MC710. MC710 dose is denoted as FVIa 
dose. Scheme d) shows the time course of repeated infusions of APCC. The experiment was performed 
using three monkeys in each group. At pre-administrations FDP level was 0.44 ± 0.24 ng mL-1 (n=12) 
and at 30 min after the final administration of the agents a), b), c), and d) were 3.37 ± 3.59, 5.87 ± 2.64, 
2.93 ± 0.42, and 8.57 ± 2.17 ng mL-1 (n=3), respectively. 
Fig. 8. Design for the thrombognenic test for MC710 
5. Summary of phase I clinical study 
5.1 Outline of the trial  
Phase I clinical study of MC710 has been completed. In this study, PK and PD parameters and 
the safety of single doses of MC710 were investigated in 11 hemophilia patients with inhibitors 
in a non-bleeding state. A total of 25 administrations of MC710 were made to the subjects (7 
hemophilia A patients with inhibitors and 4 hemophilia B patients with inhibitors) at 5 doses 
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of MC710 (20, 40, 80, 100 and 120 g kg-1 (as FVIIa dose)) in addition to the administrations of 
rFVIIa 120 μg kg-1, and APCC 50 U kg-1 or 75 U kg-1 as active controls [53]. 
5.2 Pharmacokinetic analysis  
PK parameters were calculated based on FVII:C, FVII:Ag, FX:C and FX:Ag levels. As shown 
in Figs. 9A-D, those levels rapidly increased after administration of MC710. FVII:C and 
FVII:Ag levels returned to pre-administration values during 12 to 24 h after the 
administration, and increased levels of FX:C and FX:Ag persisted in the blood until 48 h 
after the administration of MC710 at 80 μg kg-1 or more. The mean t1/2 of FVII:C and FVII:Ag 
in the MC710-infused group was 2.1~3.4 h and 3.5~4.9 h, respectively, and that of FX:C and 
FX:Ag was 20.2~23.2 h and 22.8~27.5 h, respectively, shorter than reported values (t1/2 of 
FX:C 24~56 h [42, 43]). On the other hand, the recovery of FVII:C and FVII:Ag in the MC710-
infused group was 70.7~90.7% and 50.0~92.0%, respectively, and that of FX:C and FX:Ag 
was 98.7~120.9% and 94.0~109.4%, respectively. PK parameters of FVIIa were similar to 
previously reported values for rFVIIa [41]. 
 
A. FVII:C B. FVII:Ag
C. FX:C D. FX:Ag
 
Time-dependent changes in the pharmacokinetics of FVII:C (Panel A), FVII:Ag (Panel B), FX:C (Panel C) 
and FX:Ag (Panel D) are shown. Enlarged figures of the changes in FVII:C and FVII:Ag until 6 hr after 
administration are shown in the right upper corner of each graph. The mark represents the mean ± SD. 
MC710 doses are denoted by the following color symbols: 20 μg kg-1, (-●-); 40 μg kg-1, (-●-); 80 μg kg-1, 
(-●-); 100 μg kg-1, (-●-); 120 μg kg-1, (-●-). MC710 doses are denoted as FVIIa dose.  
Fig. 9. Changes in pharmacokinetic parameters after the administration of MC710 to 
hemophilia patients with inhibitors(53) 
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5.3 Pharmacodynamic analysis 
APTT and PT were measured as PD parameters. APTT, prolonged 120 sec or more before 
administration, improved in a dose-dependent manner after administration of MC710, and 
the effect persisted for 12 h at all doses (Fig. 10A). At MC710 doses of more than 100 μg kg-1,  
 
A. APTT B. PT
 
Time-dependent changes in APTT (Panel A) and PT (Panel B) are shown. The normal ranges for healthy 
individuals (- - -) for APTT were defined as 42.5 (upper limit) and 23.5 (lower limit) sec and for PT as 
12.8 (upper limit) and 9.9 (lower limit) sec. The mark represents the mean ± SD. MC710, rFVIIa 
(NovoSeven®) and APCC (FEIBA®) doses are denoted by the following color symbols: MC710 (as FVIIa 
dose); 20 μg kg-1, (-●-); 40 μg kg-1, (-●-); 80 μg kg-1, (-●-); 100 μg kg-1, (-●-); 120 μg kg-1, (-●-); 
rFVIIa; 120 μg kg-1, (-▲-); APCC; 50 U kg-1, (-■-); 75 U kg-1, (-■-). 
Fig. 10. Changes in pharmacodynamic parameters after the administration of MC710 to 
hemophilia patients with inhibitors(53) 
the APTT was especially close to the normal range. Even 6 h after the administration of 
more than 100 μg kg-1 of MC710, the APTT was shorter than that immediately after the 
administration of 120 μg kg-1 of rFVIIa and 75 U kg-1 of APCC. It is expected that from the 
evaluation based on the level of improvement in APTT, the hemostatic effect immediately 
after the administration of MC710 at over 100 μg kg-1 might be equivalent to that of FVIII or 
FIX replacement therapy (replacement level 20 to 50% of these factors). 
The PT reached approximately 6 sec (the determination limit) after administration of all 
doses of MC710 except for 20 μg kg-1 and remained at that level for up to 2 h. At 6 h after the 
administration of 80, 100 and 120 μg kg-1 of MC710, the PT was shorter than that after the 
administration of 120 μg kg-1 of rFVIIa. The reduction in PT persisted for 12 h at all doses 
(Fig. 10B). The PT after the administration of 40, 80, 100 and 120 μg kg-1 of MC710 was 
shorter than that for 75 U kg-1 of APCC.  
5.4 DIC and other safety concerns 
TAT and F1+2 were increased after the administration of MC710 indicating the activation of 
prothrombin in blood flow; however, similar increases were also observed after the 
administration of rFVIIa and APCC [54, 55]. No serious or severe adverse events were 
observed within 4 weeks after the administration of MC710 and no subject discontinued 
treatment due to an adverse event. Also, no clinical symptoms or changes in laboratory tests 
(platelet count, fibrinogen, D-dimer) indicating a hypercoagulable state such as DIC were 
detected (data not shown). In addition, the results of virologic and serologic tests confirmed 
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that no subject developed a new viral antigen or produced a new antibody after the 
administration of MC710.  
6. Conclusion and future perspectives 
In this review, we described the rationale for the combined use of FVIIa and FX, the 
manufacturing process of FVIIa/FX mixture, MC710, and the treatment’s prospective 
efficacy and safety. We also outlined the results of a Phase I clinical study. In the study, PK 
and PD parameters changed in a dose-dependent manner after the administration of MC710 
and the changes in the PD parameters (APTT and PT) were equal to or greater than those in 
rFVIIa and APCC. Furthermore, MC710 was safely administered at doses of up to 120 μg kg-1 
and no serious or severe adverse events, including DIC, were observed.  
It was recently reported that the combination of APCC and rFVIIa is safe and effective in the 
treatment of bleeding that is unresponsive to monotherapy [56]. This report supports our 
hypothesis that the FVIIa/FX mixture, MC710, would be a more potent bypassing agent 
than clinically available bypassing agents. Phase II clinical studies in hemophilia patients 
with inhibitors who are hemorrhaging have been completed in Japan and MC710 is 
expected to be used as an alternative to APCC and rFVIIa in the near future. 
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